Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Timorshah Habibzada"'
Autor:
Jonas S. Heitmann, Claudia Tandler, Maddalena Marconato, Annika Nelde, Timorshah Habibzada, Susanne M. Rittig, Christian M. Tegeler, Yacine Maringer, Simon U. Jaeger, Monika Denk, Marion Richter, Melek T. Oezbek, Karl-Heinz Wiesmüller, Jens Bauer, Jonas Rieth, Marcel Wacker, Sarah M. Schroeder, Naomi Hoenisch Gravel, Jonas Scheid, Melanie Märklin, Annika Henrich, Boris Klimovich, Kim L. Clar, Martina Lutz, Samuel Holzmayer, Sebastian Hörber, Andreas Peter, Christoph Meisner, Imma Fischer, Markus W. Löffler, Caroline Anna Peuker, Stefan Habringer, Thorsten O. Goetze, Elke Jäger, Hans-Georg Rammensee, Helmut R. Salih, Juliane S. Walz
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and e
Externí odkaz:
https://doaj.org/article/b32dbe5fcabf453983d2e107f672acc4
Autor:
Thorsten Oliver Goetze, Alexander Stein, Sylvie Lorenzen, Timorshah Habibzada, Eray Goekkurt, Peter Herhaus, Disorn Sookthai, Kristina Ihrig, Claudia Pauligk, Salah-Eddin Al-Batran
Publikováno v:
Journal of Clinical Oncology. 41:359-359
359 Background: Based on results of prior trials (TAGS, REGARD, RAINBOW), it seems promising to combine Ramucirumab (Ram) beyond progression (PD) with TAS-102 (trifluridine/tipiracil). The purpose of RE-ExPEL is to investigate the tolerability, safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0212ec85802f0688ac1d8a0cc15461d7
https://doi.org/10.1200/jco.2023.41.4_suppl.359
https://doi.org/10.1200/jco.2023.41.4_suppl.359